COVID-19 and a low vitamin D state share common risk factors, which might explain why vitamin D deficiency has been linked with higher COVID-19 mortality. Moreover, measures of serum vitamin D may become lower during systemic inflammatory responses, further confounding the association via reverse causality. In this prospective study (recruited over 12 months), we examined whether the association between a low vitamin D state and in-hospital mortality due to SARS-CoV-2 pneumonia in unvaccinated subjects is explained by (i) the presence of shared risk factors (e.g., obesity, advanced age) or (ii) a reduction in serum 25(OH)D due to COVID-19 (i.e., reverse causality). In this cohort of 232 (mean age = 56 years) patients (all had SARS-CoV-2 diagnosed via PCR AND required supplemental oxygen therapy), we failed to find an association between serum vitamin D and levels of CRP, or other inflammatory markers. However, the hazard ratio for mortality for subjects over 70 years of age (13.2) and for subjects with a serum 25(OH)D level less than 30 nmol·L−1 (4.6) remained significantly elevated even after adjustment for gender, obesity and the presence of diabetes mellitus. Subjects 70 years had significantly higher mortality with a serum 25(OH)D less than 30 nmol·L−1 (11.8% and 55%), than with a serum 25(OH)D greater than 30 nmol·L−1 (2.2% and 25%). Unvaccinated Caucasian adults with a low vitamin D state have higher mortality due to SARS CoV-2 pneumonia, which is not explained by confounders and is not closely linked with elevated serum CRP.
Background: Adults with hypertension (HTN) have fewer cardiovascular events if controlled within the first 6 months after diagnosis, during which time they are excluded from many HTN control metrics. We compared BP control rates (BP <140/90) from 6 to 42 months in adults with HTN who did or did not have treatment initiated during the first month following diagnosis, irrespective of subsequent treatment initiation or intensification (TI). Methods: A patient cohort from 5 diverse healthcare organizations, engaged in a quality improvement program, was identified with previously undiagnosed and untreated HTN. TI and BP control were assessed by measuring the period prevalence of visit BP control and TI on uncontrolled visits, then compared with the time since diagnosis (TSD) up to 42 months. Groups were stratified by treatment initiation status during the first month. Results: A prospective cohort of 14,328 newly diagnosed and untreated persons with HTN was identified, mean age 56.2±14.7 years. Patients with TI during the first month had higher rates of BP control at 6 (56.2% vs 46.2%, p<0.001) through 30 months (65.9% vs 61.4%, p<0.001) than those initially untreated. Patients initiated during the first month were less likely to receive additional intensifications (OR 0.68, 95% CI [0.63-0.74]). Conclusion: TI in the first month after diagnosis results in better BP control at 6 months, which has prognostic importance and coincides with the time when these individuals impact standard HTN control metrics. Of concern, TI during the first month after diagnosis was insufficient to achieve control rates ≥70% and lowered the probability of subsequent TI.